Miraki-Moud, Farideh, Ariza-McNaughton, Linda, KoKo, Thinzar, Othman, Jad, Stronge, Randal, de Bono, Johann, Russell, Nigel, Thomas, Ian, Gilkes, Amanda, Burnett, Alan, Santiago, Leandro Rodrigues, Cafferty, Fay, Taussig, Leo, Thornhill, Allan, O’Connor, Simon, Bonnet, Dominique and Taussig, David C.
2025.
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival.
Leukemia
10.1038/s41375-025-02752-x
|
|
|
| Lachowiez, Curtis A., Asimomitis, Georgios, Bernard, Elsa, Devlin, Sean M., Tazi, Yanis, Creignou, Maria, Germing, Ulrich, Gattermann, Norbert, Gilkes, Amanda, Thomas, Ian, Bullinger, Lars, Döhner, Konstanze, Malcovati, Luca, Othman, Jad, Dillon, Richard, Eisfeld, Ann-Kathrin, Nicolet, Deedra, Issa, Ghayas C., Daver, Naval, Kadia, Tapan M., DiNardo, Courtney D., Ravandi, Farhad, Garcia-Manero, Guillermo, Montalban-Bravo, Guillermo, Russell, Nigel, Cazzola, Mario, Döhner, Hartmut, Huntly, Brian JP., Hasserjian, Robert P., Hellström-Lindberg, Eva, Papaemmanuil, Elli and Loghavi, Sanam 2025. Multi-modal and data-driven assessment of myeloid neoplasms refines classification across disease states. Blood Cancer Discovery 6 (5) , pp. 425-436. 10.1158/2643-3230.bcd-25-0047 |
|
|
Döhner, Konstanze, Döhner, Hartmut, Späth, Daniela, Kapp‐Schwoerer, Silke, Gilkes, Amanda, Thomas, Ian, Johnson, Sean, Potter, Nicola, Bevan, Yana, Othman, Jad, Russell, Nigel H., Röllig, Christoph, Thiede, Christian, Bornhäuser, Martin, Oellerich, Thomas, Hood, Tressa, Elder, Jenna, Carvajal, Luis A., DiMartino, Jorge and Dillon, Richard
2025.
A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction.
HemaSphere
9
(8)
, e70198.
10.1002/hem3.70198
|
|
|
Potter, Nicola, Jovanovic, Jelena, Ivey, Adam, Othman, Jad, Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Gilkes, Amanda, Runglall, Manohursingh, Kanda, Anju, Thomas, Ian, Johnson, Sean, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Villiers, William, Knapper, Steven, Khwaja, Asim, McMullin, Mary Frances, Cavenagh, Jamie, Overgaard, Ulrik Malthe, Clark, Richard E, Solomon, Ellen, Freeman, Sylvie D, Hills, Robert, Burnett, Alan, Russell, Nigel, Dillon, Richard and UK AML Research Network
2025.
Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.
The Lancet Haematology
12
(5)
, e346-e356.
10.1016/S2352-3026(25)00037-7
|
|
|
Versluis, Jurjen, Metzner, Marlen, Wang, Ariel, Gradowska, Patrycja, Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Jakobsen, Niels Asger, Kennedy, Alison, Moore, Rachel, Boertjes, Emma, Vonk, Christian M., Kavelaars, Francois G., Rijken, Melissa, Gilkes, Amanda, Schwab, Claire, Beverloo, H. Berna, Manz, Markus, Visser, Otto, Van Elssen, Catharina H.M.J., de Weerdt, Okke, Tick, Lidwine W., Biemond, Bart J., Vekemans, Marie-Christiane, Freeman, Sylvie D., Harrison, Christine J., Cook, Jonathan A., Dennis, Mike, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, Thomas, Ian, Craddock, Charles, Ossenkoppele, Gert J., Löwenberg, Bob, Russell, Nigel, Valk, Peter J.M. and Vyas, Paresh
2024.
Risk stratification in older intensively treated patients with AML.
Journal of Clinical Oncology
42
(34)
, pp. 4084-4094.
10.1200/JCO.23.02631
|
|
|
Russell, Nigel H., Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Hills, Robert K., Thomas, Ian, Gilkes, Amanda, Marquez Almuina, Nuria, Burns, Sarah, Marsh, Lucy, Vyas, Paresh, Metzner, Marlen, McCarthy, Nicholas, Andrew, Georgia, Byrne, Jennifer, Sellar, Rob S., Kelly, Richard, Cahalin, Paul, Malthe Overgaard, Ulrik, Mehta, Priyanka, Dennis, Mike, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441 and Freeman, Sylvie D.
2024.
Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients With AML: Results From the NCRI AML18 Trial.
Journal of Clinical Oncology
10.1200/JCO.24.00259
|
|
|
| Voso, Maria Teresa, Guarnera, Luca, Lehmann, Sören, Döhner, Konstanze, Döhner, Hartmut, Platzbecker, Uwe, Russell, Nigel H., Dillon, Richard James, Thomas, Ian, Ossenkoppele, Gert J, Haferlach, Torsten, Vignetti, Marco, La Sala, Edoardo, Piciocchi, Alfonso, Fazi, Paola, Villaverde Ramiro, Ángela, Tur Giménez, Laura, Gurnari, Carmelo, Bullinger, Lars and Hernandez, Jesus M. 2024. Acute promyelocytic leukemia: Long-term outcomes from the HARMONY project. Blood 10.1182/blood.2024026186 |
|
| Rodríguez-Arbolí, Eduardo, Othus, Megan, Freeman, Sylvie D., Buccisano, Francesco, Ngai, Lok Lam, Thomas, Ian, Palmieri, Raffaele, Cloos, Jacqueline, Johnson, Sean, Meddi, Elisa, Russell, Nigel H., Venditti, Adriano, Gradowska, Patrycja, Ossenkoppele, Gert J., Löwenberg, Bob and Walter, Roland B. 2024. Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML) [Letter to the Editor]. Leukemia 38 (10) 10.1038/s41375-024-02378-5 |
|
|
Othman, Jad, Potter, Nicola, Ivey, Adam, Tazi, Yanis, Papaemmanuil, Elli, Jovanovic, Jelena, Freeman, Sylvie D., Gilkes, Amanda Frances, Gale, Rosemary E., Rapoz-D'Silva, Tanya, Runglall, Manohursingh, Kleeman, Michelle, Dhami, Pawan, Thomas, Ian, Johnson, Sean, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Cavenagh, James Durrell, Kottaridis, Panagiotis, Arnold, Claire, Ommen, Hans Beier, Overgaard, Ulrik Malthe, Dennis, Mike, Burnett, Alan Kenneth, Wilhelm-Benartzi, Charlotte S. ORCID: https://orcid.org/0000-0003-4927-6158, Huntly, Brian J.P., Russell, Nigel H. and Dillon, Richard James
2024.
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML.
Blood
144
(7)
, pp. 714-728.
10.1182/blood.2024024310
|
|
|
Othman, Jad, Potter, Nicola, Ivey, Adam, Jovanovic, Jelena, Runglall, Manohursingh, Freeman, Sylvie D., Gilkes, Amanda, Thomas, Ian, Johnson, Sean, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Cavenagh, Jamie, Kottaridis, Panagiotis, Arnold, Claire, Ommen, Hans Beier, Overgaard, Ulrik Malthe, Dennis, Mike, Burnett, Alan, Wilhelm-Benartzi, Charlotte, Dillon, Richard and Russell, Nigel H.
2024.
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Blood
143
(19)
, pp. 1931-1936.
10.1182/blood.2023023096
|
|
|
Copland, Mhairi, Ariti, Cono ORCID: https://orcid.org/0000-0001-7615-0935, Thomas, Ian F., Upton, Laura, Sydenham, Mia, Mehta, Priyanka, Islam, Shahid, Kjeldsen, Lars, Burnett, Alan K., Hills, Robert K. ORCID: https://orcid.org/0000-0003-0166-0062, Russell, Nigel, Dennis, Mike and UK NCRI AML Study Group
2024.
A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI ‐1 trial.
British Journal of Haematology
204
(3)
, pp. 871-876.
10.1111/bjh.19220
|
|
|
Kitson, Terri ORCID: https://orcid.org/0000-0001-6333-046X, Osborne, Emma, Noble, Simon ORCID: https://orcid.org/0000-0001-5425-2383, Pease, Nikki, Alikhan, Raza, Bryant, Catherine, Groves, Tristan, Wallace, Rebecca, Walker, Sarah, Seddon, Kathy, Smith, Deb, Raisanen, Lawrence, Smith, Joanna ORCID: https://orcid.org/0000-0003-4234-6686, Thomas, Ian, Upton, Laura and Casbard, Angela ORCID: https://orcid.org/0000-0001-6241-3052
2023.
HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care.
BMJ Open
13
(9)
, e073049.
10.1136/bmjopen-2023-073049
|
|
|
Mussai, Francis, De Santo, Carmela, Cheng, Paul, Thomas, Ian F., Ariti, Cono ORCID: https://orcid.org/0000-0001-7615-0935, Upton, Laura, Scarpa, Ugo, Stavrou, Victoria, Sydenham, Mia, Burnett, Alan K., Knapper, Steven K. ORCID: https://orcid.org/0000-0002-6405-4441, Mehta, Priyanka, McMullin, Mary F., Copland, Mhairi, Russell, Nigel H. and Dennis, Mike
2023.
A randomised evaluation of low‐dose Ara‐ C plus pegylated recombinant arginase BCT ‐100 versus low dose Ara‐ C in older unfit patients with acute myeloid leukaemia: Results from the LI ‐1 trial.
British Journal of Haematology
200
(5)
, pp. 573-578.
10.1111/bjh.18560
|
|
|
Loo, Sun, Dillon, Richard, Ivey, Adam, Anstee, Natasha S, Othman, Jad, Tiong, Ing Soo, Potter, Nicola, Jovanovic, Jelena, Runglall, Manohursingh, Chua, Chong Chyn, Bajel, Ashish, Ritchie, David, Gray, Kelli, Yeoh, Zhi Han, McBean, Michelle, Gilkes, Amanda, Thomas, Ian, Johnson, Sean, Russell, Nigel H and Wei, Andrew H.
2022.
Pre-transplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines post-transplant clinical outcome [Letter].
Blood
140
(22)
, pp. 2407-2411.
10.1182/blood.2022016567
|
|
|
Freeman, Sylvie D, Thomas, Abin, Thomas, Ian, Vyas, Paresh, Gilkes, Amanda, Metzner, Marlen, Jakobsen, Niels Asger, Kennedy, Alison, Moore, Amy, Marquez Almuina, Nuria, Burns, Sarah, King, Sophie, Andrew, Georgia M., Gallagher, Kathleen M.E., Sellar, Rob, Cahalin, Paul, Weber, Duruta, Dennis, Mike, Mehta, Priyanka, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441 and Russell, Nigel H.
2022.
A randomized comparison of the fractionated versus single dose schedule of Gemtuzumab Ozogamicin at induction with determinants of benefit for older AML patients: UK NCRI AML18 trial results.
Blood
140
(S1)
, pp. 532-533.
10.1182/blood-2022-162245
|
|
| Döhner, Konstanze, Döhner, Hartmut, Weber, Daniela, Kapp-Schwoerer, Silke, Gilkes, Amanda, Thomas, Ian, Johnson, Sean, Potter, Nicola, Bevan, Yana, Othman, Jad, Russell, Nigel H., Röllig, Christoph, Thiede, Christian, Bornhaeuser, Martin, Oellerich, Thomas, Elder, Jenna, Carvajal, Luis A., To, Zung, DiMartino, Jorge and Dillon, Richard 2022. Analysis of patient-level data from 3 cooperative group trials confirms a survival advantage for NPM1m patients achieving MRD-negative CR after intensive induction. Blood 140 (S1) , pp. 6293-6294. 10.1182/blood-2022-159212 |
|
Love, Sharon B., Cafferty, Fay, Snowdon, Claire, Carty, Karen, Savage, Joshua, Pallmann, Philip ORCID: https://orcid.org/0000-0001-8274-9696, McParland, Lucy, Brown, Louise, Masters, Lindsey, Schiavone, Francesca, Hague, Dominic, Townsend, Stephen, Amos, Claire, South, Annabelle, Sturgeon, Kate, Langley, Ruth, Maughan, Timothy, James, Nicholas, Hall, Emma, Kernaghan, Sarah, Bliss, Judith, Turner, Nick, Tutt, Andrew, Yap, Christina, Firth, Charlotte, Kong, Anthony, Mehanna, Hisham, Watts, Colin, Hills, Robert, Thomas, Ian, Copland, Mhairi, Bell, Sue, Sebag-Montefiore, David, Jones, Robert, Parmar, Mahesh K B and Sydes, Matthew R
2022.
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
Trials
23
, 757.
10.1186/s13063-022-06680-4
|
|
|
| Russell, Nigel H., Hills, Robert K., Kjeldsen, Lars, Clark, Richard E., Ali, Sahra, Cahalin, Paul, Thomas, Ian F. and Burnett, Alan K. 2022. A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. British Journal of Haematology 198 (3) , pp. 528-534. 10.1111/bjh.18195 |
|
|
Tazi, Yanis, Arango-Ossa, Juan E., Zhou, Yangyu, Bernard, Elsa, Thomas, Ian, Gilkes, Amanda, Freeman, Sylvie, Pradat, Yoann, Johnson, Sean J., Hills, Robert, Dillon, Richard, Levine, Max F., Leongamornlert, Daniel, Butler, Adam, Ganser, Arnold, Bullinger, Lars, Döhner, Konstanze, Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Adams, Richard ORCID: https://orcid.org/0000-0003-3915-7243, Döhner, Hartmut, Campbell, Peter J., Burnett, Alan K., Dennis, Michael, Russell, Nigel H., Devlin, Sean M., Huntly, Brian J. P. and Papaemmanuil, Elli
2022.
Unified classification and risk-stratification in Acute Myeloid Leukemia.
Nature Communications
13
(1)
, 4622.
10.1038/s41467-022-32103-8
|
|
|
Russell, Nigel H., Hills, Robert K., Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Thomas, Ian, Kjeldsen, Lars, Dennis, Mike, Craddock, Charles, Freeman, Sylvie, Clark, Richard E. and Burnett, Alan K.
2022.
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukaemia: results of the NCRI acute myeloid leukemia 16 trial.
Haematologica
107
(7)
, pp. 1518-1527.
10.3324/haematol.2021.279010
|
|
|
Coats, Thomas, Bean, Daniel, Basset, Aymeric, Sirkis, Tamir, Brammeld, Jonathan, Johnson, Sean, Thomas, Ian, Gilkes, Amanda, Raj, Kavita, Dennis, Mike, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, Mehta, Priyanka, Khwaja, Asim, Hunter, Hannah, Tauro, Sudhir, Bowen, David, Jones, Gail, Dobson, Richard, Russell, Nigel and Dillon, Richard
2022.
A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
British Journal of Haematology
196
(6)
, pp. 1337-1343.
10.1111/bjh.18013
|
|
|
| Stimpson, Madeleine L., Wolf, Julia S., Williams, Emily L., Lait, Philippa J. P., Schewitz?Bowers, Lauren P., Greenwood, Rosemary, Pell, Julie, Thomas, Ian, Lee, Richard W. J. and Bradbury, Charlotte A. 2022. CD4+ T cells from patients with glucocorticoid-refractory immune thrombocytopenia have altered cytokine expression. British Journal of Haematology 196 (4) , pp. 1113-1117. 10.1111/bjh.17884 |
|
|
Dennis, Mike, Thomas, Ian F., Ariti, Cono ORCID: https://orcid.org/0000-0001-7615-0935, Upton, Laura, Burnett, Alan K., Gilkes, Amanda, Radia, Rohini, Hemmaway, Claire, Mehta, Priyanka, Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, Clark, Richard E., Copland, Mhairi, Russell, Nigel and Hills, Robert K.
2021.
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients.
Blood Advances
5
(24)
, pp. 5621-5625.
10.1182/bloodadvances.2021005038
|
|
|
| Bradbury, Charlotte A., Pell, Julie, Hill, Quentin, Bagot, Catherine, Cooper, Nichola, Ingram, Jenny, Breheny, Katie, Kandiyali, Rebecca, Rayment, Rachel, Evans, Gillian, Talks, Kate, Thomas, Ian and Greenwood, Rosemary 2021. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. New England Journal of Medicine 385 (10) , pp. 885-895. 10.1056/NEJMoa2100596 |
|
Dennis, Mike, Burnett, Alan, Hills, Robert, Thomas, Ian, Ariti, Cono ORCID: https://orcid.org/0000-0001-7615-0935, Severinsen, Marianne, Hemmaway, Claire, Greaves, Paul, Clark, Richard, Copland, Mhairi and Russell, Nigel
2021.
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
British Journal of Haematology
194
(2)
, pp. 298-308.
10.1111/bjh.17501
|
|
Burnett, Alan K., Russell, Nigel H., Hills, Robert K., Knapper, Stephen ORCID: https://orcid.org/0000-0002-6405-4441, Freeman, Sylvie, Huntly, Brian, Clark, Richard E., Thomas, Ian F., Kjeldsen, Lars, McMullin, Mary Frances, Drummond, Mark, Kell, Jonathan and Spearing, Ruth
2021.
Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses.
Journal of Clinical Oncology
39
(8)
, pp. 890-901.
10.1200/JCO.20.01170
|
|
|
Greenwood, Rosemary, Pell, Julie, Foscarini-Craggs, Paula, Wale, Katharine, Thomas, Ian and Bradbury, Charlotte
2020.
Letter on Predicting the number of sites needed to deliver a multicentre clinical trial within a limited time frame in the UK.
Trials
21
(1)
, 873.
10.1186/s13063-020-04798-x
|
|
|
Burnett, Alan K., Hills, R K ORCID: https://orcid.org/0000-0003-0166-0062, Nielsen, O J, Freeman, S, Ali, A, Cahalin, P, Hunter, A, Thomas, Ian and Russell, N H
2018.
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial.
Leukemia
32
, pp. 2693-2714.
10.1038/s41375-018-0148-3
|
|
|
Freeman, Sylvie D., Hills, Robert K. ORCID: https://orcid.org/0000-0003-0166-0062, Virgo, Paul, Khan, Naeem, Couzens, Steve, Dillon, Richard, Gilkes, Amanda, Upton, Laura, Nielsen, Ove Juul, Cavenagh, James D., Jones, Gail, Khwaja, Asim, Cahalin, Paul, Thomas, Ian, Grimwade, Davied, Burnett, Alan K. and Russell, Nigel H.
2018.
Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations.
Journal of Clinical Oncology
36
(14)
, pp. 1486-1497.
10.1200/JCO.2017.76.3425
|
|
|
Knapper, Steven ORCID: https://orcid.org/0000-0002-6405-4441, Russell, Nigel, Gilkes, Amanda, Hills, Robert K. ORCID: https://orcid.org/0000-0003-0166-0062, Gale, Rosemary E., Cavenagh, James D., Jones, Gail, Kjeldsen, Lars, Grunwald, Michael R., Thomas, Ian, Konig, Heiko, Levis, Mark J. and Burnett, Alan K.
2017.
A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
Blood
129
(9)
, pp. 1143-1154.
10.1182/blood-2016-07-730648
|
|
|
Burnett, Alan, Cavenagh, Jamie, Russell, Nigel, Hills, Robert ORCID: https://orcid.org/0000-0003-0166-0062, Kell, Jonathan, Jones, Gail, Nielsen, Ove Juul, Khwaja, Asim, Thomas, Ian and Clark, Richard
2016.
Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 trial.
Haematologica
101
(6)
, pp. 724-731.
10.3324/haematol.2016.141937
|
|
|
Burnett, A. K., Russell, N. H., Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Kell, J., Cavenagh, J., Kjeldsen, L., McMullin, M.-F., Cahalin, P., Dennis, M., Friis, L., Thomas, Ian, Milligan, D. and Clark, R. E.
2015.
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
Blood
125
(25)
, pp. 3878-3885.
10.1182/blood-2015-01-623447
|
|
Khan, Naeem, Freeman, Sylvie D., Virgo, Paul, Couzens, Steve, Richardson, Peter, Thomas, Ian, Grech, Angela, Vyas, Paresh, Grimwade, David, Russell, Nigel H., Burnett, Alan K. and Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062
2015.
An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts.
British Journal of Haematology
170
(1)
, pp. 80-84.
10.1111/bjh.13398
|
|
Dennis, M., Russell, N., Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062, Hemmaway, C., Panoskaltsis, N., McMullin, M. F., Kjeldsen, L., Dignum, H., Thomas, Ian, Clark, R. E., Milligan, D. and Burnett, Alan
2015.
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Blood
125
(19)
, pp. 2923-2932.
10.1182/blood-2014-10-608117
|
|



Up a level